[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"extracorporeal-membrane-oxygenation-ecmo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:extracorporeal-membrane-oxygenation-ecmo":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,84,125,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652915","prevalence-and-measurement-of-delayed-gastric-emptying-in-patients-receiving-extracorporeal-membrane-oxygenation-100652915",false,"NCT07779174","Prevalence and Measurement of Delayed Gastric Emptying in Patients Receiving Extracorporeal Membrane Oxygenation","A Prospective Observational Study Exploring the Prevalence and Measurement of Delayed Gastric Emptying in Critically Ill Adults Receiving Extracorporeal Membrane Oxygenation","PROPEL-ECMO","* INCLUSION CRITERIA (non-ECMO group):\n\n  * Within 72 hours of Guy's \\& St Thomas' ICU admission\n  * Mechanically ventilated adults (≥18 years)\n  * Receiving enteral nutrition (liquid nutrition) via a gastric (nasogastric or orogastric) feeding tube\n  * Informed consent \u002F advice for participation by consultee\n  * Availability of study investigator or other trained healthcare professional on site to complete gastric emptying (stomach emptying) measurements\n* INCLUSION CRITERIA (ECMO group):\n\n  * Within 72 hours of Guy's \\& St Thomas' ICU admission\n  * Mechanically ventilated adults (≥18 years)\n  * Receiving enteral nutrition (liquid nutrition) via a gastric (nasogastric or orogastric) feeding tube\n  * Informed consent \u002F advice for participation by consultee\n  * Availability of study investigator or other trained healthcare professional on site to complete gastric emptying (stomach emptying) measurements\n  * Receiving either veno-venous or veno-arterial ECMO\n* EXCLUSION CRITERIA:\n\n  * Pregnancy\n  * History of gastroparesis (long-term slow stomach emptying)\n  * Current acute or long-term gastrointestinal pathology (stomach or bowel problem) that may influence gastric emptying (e.g. inflammatory bowel disease, coeliac disease, pancreatic exocrine insufficiency)\n  * Current contraindication to enteral nutrition (liquid nutrition) (e.g. clinical or radiological evidence of bowel obstruction, bowel ischaemia, ileus, upper gastrointestinal bleeding)\n  * Enteral nutrition (liquid nutrition) through a gastrostomy, jejunostomy or nasojejunal feeding tube\n  * Current or previous oesophageal, stomach or major small bowel surgery\n  * Known anatomical abnormality of the stomach (e.g. hiatus hernia)\n  * Pericardial \u002F abdominal drains or surgical wounds obstructing site of ultrasound scanning\n  * Nuclear medicine therapeutic administration, or diagnostic scintigraphy investigation in the previous 72 hours\n  * Unlikely to survive or withdrawal of life-sustaining treatment expected in the next 48 hours","ALL","18 Years","80 Years",{"count":21,"type":22},72,"ESTIMATED","OBSERVATIONAL","* The goal of this observational study is to learn whether the stomach takes longer to empty in patients on the intensive care unit who are receiving ECMO (a machine that temporarily takes over the role of the lungs and heart) compared to patients receiving support through a breathing machine (mechanical ventilation) only. It will also find the best way to measure stomach emptying at the bedside.\n* The main questions it aims to answer are:\n\n  * What is the prevalence of slow stomach emptying and other stomach or bowel problems in patients receiving ECMO, compared to patients receiving mechanical ventilation but not receiving ECMO? (Stage A)\n  * What is the best bedside method to measure stomach emptying in patients receiving ECMO? (Stage B)\n* Stage A of the study will involve measuring stomach emptying in study participants within four days of ICU admission, using two bedside methods:\n\n  * 'Residual volumes' (removing liquid nutrition left in the stomach with a syringe, after this has been given through the participant's usual feeding tube)\n  * A stomach ultrasound scan The researchers will check for differences between patients receiving ECMO versus no ECMO, and how this relates to the nutrition patients receive and how well or unwell they become in ICU.\n* In a smaller subgroup of patients receiving ECMO and participating in Stage B of the study, the researchers will also use scintigraphy. This is a standard research scan that tracks how the stomach empties by mixing a small, safe amount of radioactivity in the participant's usual liquid nutrition. The researchers will compare stomach emptying results from 'residual volumes' and stomach ultrasound with scintigraphy.",[26,27,28,29],"Gastric Emptying","Delayed Gastric Emptying","Critical Illness","ExtraCorporeal Membrane Oxygenation (ECMO)",[31,28,32,33,34],"Gastric emptying","Extracorporeal Membrane Oxygenation","Delayed gastric emptying","Nutrition","NOT_YET_RECRUITING","2026-08-19",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":22},"2026-09",{"date":43,"type":22},"2028-06",{"name":45,"class":46},"Guy's and St Thomas' NHS Foundation Trust","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100647280","closed-incision-npwt-to-prevent-wound-complications-post-ecmo-100647280","NCT07709546","Closed Incision NPWT to Prevent Wound Complications Post-ECMO","The Prophylactic Effect of Closed Incision Negative Pressure Therapy on Vascular Entry Site Complications Following ECMO Decannulation","PREVENT-ECMO","Inclusion Criteria:\n\n* Patient is aged 18 years or older\n* Is currently receiving ECMO therapy and is eligible for weaning from the device\n* The patient must have at least one cannula inserted at the groin site\n* (Proxy) informed consent\n\nExclusion Criteria:\n\n* Duration ECMO run \\\u003C 24 hours\n* Expected death within 24 hours after decannulation\n* Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+)\n* Wound closure is not possible after decannulation.\n* Presence of drain in the wound site\n* Participants who are not proficient in Dutch or English, or whose legal representative is not proficient, if applicable",{"count":57,"type":22},144,"INTERVENTIONAL",[60],"NA","Patients undergoing extracorporeal membrane oxygenation (ECMO) are at increased risk of wound complications at the vascular access site after decannulation. These complications may delay recovery and increase healthcare burden. Closed incision negative pressure wound therapy (NPWT) may improve wound healing by reducing fluid accumulation and supporting the incision. This study evaluates whether prophylactic NPWT reduces wound complications compared to standard wound care following ECMO decannulation.",[29,63,64],"Wound Complications","Surgical Site Infection (SSI)",[66,32,67,68,69,70,71,63,72,73,74,75],"ECMO","Negative Pressure Wound Therapy","NPWT","Prevena","Closed Incision Negative Pressure Therapy","ciNPT","Surgical Site Infection","CRWC","Groin wound","Vascular access site","2026-07-13",{"date":78,"type":39},"2026-07-16",{"date":76,"type":22},{"date":81,"type":22},"2029-03-18",{"name":83,"class":46},"St. Antonius Hospital",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":104,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100595479","improving-sedation-practice-in-critically-ill-adult-patients-using-a-co-designed-sedation-protocol-100595479","NCT07032987","Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol","Optimising Analgosedation in Extracorporeal Membrane Oxygenation (ECMO) Using a Co-designed Analgosedation Protocol","ECMO-SED","Stage 1 (multi-centre observational study):\n\nInclusion Criteria:\n\n1. Aged 18 years and older.\n2. Receiving continuous IV infusions of analgosedation (opioids, benzodiazepines, and\u002For propofol).\n3. Receiving ECMO for moderate to severe respiratory failure (PaO2\u002FFiO2 (P\u002FF) ratio \\\u003C20 kilopascals (kPa)) for ≤ 7 days during the week of recruitment.\n4. Non-ECMO ICU patients (control group): must satisfy inclusion criteria 1 and 2, and have received mechanical ventilation for moderate to severe respiratory failure (P\u002FF ratio \\\u003C 20kPa) for at least 48 hours OR mechanical ventilation for cardiovascular disorder (out of hospital cardiac arrest, following cardiothoracic or transplant surgery or percutaneous coronary intervention or acute heart failure).\n\nExclusion Criteria:\n\n1. Anticipated length of ICU stay in recruiting centre for less than 24 hours.\n2. Withdrawal of life-sustaining treatment in the next 24 hours.\n\nStage 2 (mixed methods study):\n\nInclusion Criteria:\n\n1. Healthcare professionals working at one of two ECMO centres (St Thomas' Hospital and Royal Brompton Hospital (part of Guy's and St Thomas' NHS Foundation Trust).\n2. ECMO survivors (patients admitted to ICU and survived ECMO organ support) who have returned home, and recovered.\n3. Family members of ECMO survivors, whose relative is no longer hospitalised.\n\nExclusion Criteria:\n\n1. ECMO survivors currently receiving treatment in hospital.\n2. ECMO survivors with severe cognitive issues (issues with short-term memory and thinking).\n3. ECMO survivors who cannot communicate in English.\n4. Non-ECMO survivors and family members.","100 Years",{"count":94,"type":22},120,"Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.\n\nA sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.\n\nHowever, there are no protocols for giving sedation to ECMO patients in research papers. The investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.\n\nAims:\n\n* To describe current sedation use in ECMO patients in the UK and compare to non-ECMO critically ill patients.\n* To develop a sedation protocol for ECMO patients with input from patients, their family, and staff.\n\nDesign\u002Fmethods:\n\nStudy 1:\n\nThe investigators will study how sedation is used in adult ECMO patients and compare with non-ECMO but critically ill patients in the UK. The investigators will collect information on drug doses and pain and sedation scores. The investigators will also ask ECMO centres if they use a sedation protocol to adjust sedation doses. This information will be helpful for the design of the protocol in study 2.\n\nStudy 2:\n\nThe investigators will design a sedation protocol with input from patients, family, and staff. The investigators will organise meetings to share experiences and agree on what to include in the protocol that is considered acceptable and safe. The investigators will then assess if the protocol is safe and acceptable with staff outside the co-design group.\n\nPatient and public involvement\u002Fengagement:\n\nThe investigators received feedback from patients and family members which helped to design this proposal, the lay summary and what to measure in a trial. Patients and family members will continue to help with development of the sedation and trial protocol. They will advise how the investigators should review study findings, and support sharing of results to the public.\n\nImpact\u002Fdissemination:\n\nThe investigators will share findings through social media, patient charities, research papers and conferences.",[97,98,99,29,100,101,102,103],"Intensive Care Medicine","Respiratory Distress Syndrome (RDS)","Sedation and Analgesia","Sedation for Mechanical Ventilation","Cardiogenic Shock","Opioid Analgesia","Analgesia",[105,106,107,108,109,110,66,111,112,113,114,115],"extracorporeal membrane oxygenation","sedation","opioid","sedatives","analgosedation","mechanical ventilation","ICU","Intensive Care Unit","Critical Care","sedation protocol","analgesia","RECRUITING","2026-05-05",{"date":119,"type":39},"2026-05-08",{"date":121,"type":39},"2025-11-24",{"date":123,"type":22},"2027-08-31",{"name":45,"class":46},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":23,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":47},"100601690","plasma-biomarkers-and-platelet-morphology-of-extracorporeal-cardiopulmonary-resuscitation-100601690","NCT07113769","Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation","Explore Plasma Biomarkers and Platelet Morphological Signatures for Predicting Prognosis in Patients With Extracorporeal CardioPulmonary Resuscitation (ECPR) Using Multi-omics and Platelet Morphology Analysis","ECPR","Inclusion Criteria:\n\n1. Age between 18 and 70 years old (the age limit can be relaxed if the patient has good organ function and a good neurological prognosis after evaluation).\n2. The cardiac arrest is witnessed, and bystanders perform traditional cardiopulmonary resuscitation (CPR), and the time interval from the occurrence of cardiac arrest to the start of traditional CPR is no more than 5 minutes.\n3. The causes of cardiac arrest are reversible, such as cardiogenic, pulmonary embolism, severe hypothermia, drug poisoning, trauma, acute respiratory distress syndrome, etc.\n4. After 20 minutes of traditional CPR, there is no restoration of spontaneous circulation or hemodynamic instability, or the restoration of spontaneous circulation occurs, but the spontaneous heart rhythm cannot be maintained.\n5. The informed consent has been signed.\n\nExclusion Criteria:\n\n1. Infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, etc.\n2. Hematological diseases, such as hematological malignancies, aplastic anemia, idiopathic thrombocytopenic purpura (ITP), etc.\n3. Malignant tumors in other systems except the hematological system.\n4. Patients who have received massive plasma or platelet transfusions during hospitalization or recently.",{"count":134,"type":22},130,"1 Month","Extracorporeal cardiopulmonary resuscitation (ECPR) constitutes a pivotal emergency intervention for cardiac arrest (CA) patients. However, current eligibility criteria and prognostic assessment metrics remain substantially limited, relying predominantly on clinical symptoms and physical signs while lacking objective biomarker data. Integrating reproducible, highly sensitive, and specific proteinaceous and metabolic indicators with ultrastructural platelet alterations may hold significant implications for both ECPR administration and prognostication in CA. Therefore, the purpose of this study is to identify the plasma proteomic and metabolomic characteristics of patients with refractory cardiac arrest before and after ECPR treatment, as well as the characteristics of platelet morphological and structural changes, to search for potential specific markers that can predict CA patients who may benefit from ECPR so as to optimize treatment selection.",[29,138],"Cardiac Arrest","2026-03-19",{"date":141,"type":39},"2026-03-23",{"date":143,"type":39},"2025-09-01",{"date":145,"type":22},"2026-12-30",{"name":147,"class":46},"Central China Fuwai Hospital of Zhengzhou University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":158,"conditions":159,"keywords":163,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":47},"100582862","prospective-observational-pilot-study-of-lmwh-versus-ufh-as-ecmo-anticoagulation-in-lung-transplantation-100582862","NCT06868823","Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation: A Prospective, Observational, and Pilot Study","LUX-ET-LT","Inclusion Criteria:\n\n1. ⃣ Adults (≥18 years old).\n2. ⃣ Patients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support.\n3. ⃣ Planned perioperative anticoagulation with either UFH or LMWH, as determined by the attending anesthesiologist.\n4. ⃣ Ability to provide informed consent or consent provided by a legally authorized representative.\n\nExclusion Criteria:\n\n1. ⃣ Patients receiving ECMO as a bridge to lung transplantation.\n2. ⃣ Patients requiring postoperative continuation of ECMO.\n3. ⃣ Patients with perioperative blood loss ≥3,000 mL.\n4. ⃣ Patients undergoing lung re-transplantation.\n5. ⃣ History of severe coagulopathy or bleeding disorder.\n6. ⃣ Active use of antiplatelet or anticoagulant therapy (excluding study anticoagulants).\n7. ⃣ Known heparin-induced thrombocytopenia (HIT).\n8. ⃣ Severe liver dysfunction (Child-Pugh C) or end-stage renal disease requiring dialysis.\n9. ⃣ Pregnant or breastfeeding women.",{"count":157,"type":22},40,"The aim of this observational pilot study is to evaluate the effectiveness and safety of low-molecular-weight heparin (LMWH) compared to unfractionated heparin (UFH) as anticoagulation in perioperative ECMO during bilateral lung transplantation.\n\nThe main question this study seeks to answer is:\n\nDoes LMWH provide a safe and effective alternative to UFH for ECMO anticoagulation in lung transplantation, with reduced bleeding and thrombotic complications?\n\nPatients undergoing bilateral lung transplantation with perioperative veno-arterial (V-A) ECMO support will be assigned to one of two anticoagulation strategies:\n\nUFH group: Standard UFH anticoagulation monitored using ROTEM. LMWH group: Enoxaparin-based anticoagulation monitored using ROTEM. The study will assess perioperative blood loss, hemoglobin levels, transfusion needs, and thrombotic events. Additional analyses will include coagulation profile assessments using point-of-care (POC) tests, thrombin generation test (TGT), and laboratory coagulation parameters.",[160,161,162],"Lung Transplantation","Extracorporeal Membrane Oxygenation (ECMO)","Anticoagulants and Bleeding Disorders",[160,161,164,165,166,167,168,169,170,171],"Anticoagulation","Low-Molecular-Weight Heparin (LMWH)","Unfractionated Heparin (UFH)","Thrombosis Prevention","Bleeding Complications","Coagulation Management in Surgery","Hemorrhagic and Thrombotic Events","Perioperative Hemostasis","2025-06-09",{"date":174,"type":39},"2025-06-10",{"date":176,"type":39},"2025-05-01",{"date":178,"type":22},"2025-12-31",{"name":180,"class":46},"University Hospital, Motol"]